The European Commission has given the thumbs up for Alexza's schizophrenia and bipolar disorder drug Adasuve (loxapine) to be marketed in the EU.
Alexza's partner, Barcelona, Spain-based Grupo Ferrer, will market the drug in the EU, with launch anticipated in the third quarter...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?